NYSE - Delayed Quote USD

Annovis Bio, Inc. (ANVS)

Compare
8.77 -0.36 (-3.94%)
At close: August 28 at 4:00 PM EDT
8.77 0.00 (0.00%)
After hours: August 28 at 7:45 PM EDT
Loading Chart for ANVS
DELL
  • Previous Close 9.13
  • Open 9.13
  • Bid 8.80 x 1200
  • Ask 9.50 x 1100
  • Day's Range 8.62 - 9.15
  • 52 Week Range 4.53 - 22.49
  • Volume 208,140
  • Avg. Volume 1,775,814
  • Market Cap (intraday) 119.183M
  • Beta (5Y Monthly) 1.74
  • PE Ratio (TTM) --
  • EPS (TTM) -4.54
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 32.40

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

www.annovisbio.com

6

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ANVS

View More

Performance Overview: ANVS

Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ANVS
53.10%
S&P 500
17.24%

1-Year Return

ANVS
30.40%
S&P 500
26.93%

3-Year Return

ANVS
76.26%
S&P 500
24.01%

5-Year Return

ANVS
32.28%
S&P 500
70.84%

Compare To: ANVS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ANVS

View More

Valuation Measures

Annual
As of 8/27/2024
  • Market Cap

    119.18M

  • Enterprise Value

    115.19M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    19.68

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -183.39%

  • Return on Equity (ttm)

    -453.01%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -43.02M

  • Diluted EPS (ttm)

    -4.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.05M

Research Analysis: ANVS

View More

Company Insights: ANVS

Research Reports: ANVS

View More

People Also Watch